Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

SHISX vs. XLV: which is better?

Bottom line

SHISX vs XLV: the short answer

SHISX (Blackrock Health Sciences Opportunities Portfolio) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.

But SHISX is far broader, holding 155 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.

XLV is cheaper at 0.08% vs 1.16% — a difference of $108 a year per $10,000 invested.

Over five years, XLV returned +8.1% a year vs +5.5% for SHISX.

Updated Nov 19, 2026

SHISX vs XLV side by side

SHISXXLV
TypeMutual fundETF
Fund familyBlackRockSPDR (State Street)
CategoryHealth Care SectorHealth Care Sector
Expense ratio1.16%0.08%
Annual cost per $10k$116$8
10-yr cost on $10k (prospectus)$1,409$103
Max front load—None
12b-1 fee0.25%0.02%
1-yr return+15.9%+14.5%
5-yr return (annualized)+5.5%+8.1%
10-yr return (annualized)+9.5%+9.8%
Best quarter+17.5%+14.5%
Worst quarter−11.5%−12.7%
Net assets (fund)$5.9B$40.6B
Number of holdings15565
Portfolio turnover49%2%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearSHISXXLVDifference
2025+15.9%+14.5%+1.4%
2024+3.8%+2.5%+1.3%
2023+3.5%+2.0%+1.5%
2022−6.0%−2.1%−3.9%
2021+11.7%+25.9%−14.2%
2020+19.4%+13.3%+6.2%
2019+25.3%+20.7%+4.6%
2018+8.0%+6.3%+1.7%
2017+24.8%+21.7%+3.1%
2016−6.1%−2.8%−3.2%

Source: Fund prospectus bar charts

Holdings overlap

17 of SHISX's top 25 holdings also appear in XLV's top 25.

Shared top holdings
HoldingSHISXXLV
Eli Lilly & Company12.29%16.51%
Johnson & Johnson8.77%10.64%
Unitedhealth Group Inc6.10%6.57%
Merck & Company Inc4.94%5.52%
Gilead Sciences Inc4.19%2.73%
Abbvie Inc3.94%7.74%
Amgen Inc3.37%3.40%
Thermo Fisher Scientific Inc3.02%3.24%
Vertex Pharmaceuticals Inc2.74%2.19%
Pfizer Inc2.61%2.39%
Danaher Corp2.00%2.09%
Abbott Laboratories1.97%2.75%
Intuitive Surgical Inc1.95%2.45%
Boston Scientific Corp1.59%1.10%
Elevance Health Inc1.56%1.46%

Source: SEC Form N-PORT

SHISX top 10

  1. Eli Lilly & Company — 12.29%
  2. Johnson & Johnson — 8.77%
  3. Unitedhealth Group Inc — 6.10%
  4. Merck & Company Inc — 4.94%
  5. Gilead Sciences Inc — 4.19%
  6. Abbvie Inc — 3.94%
  7. Amgen Inc — 3.37%
  8. Thermo Fisher Scientific Inc — 3.02%
  9. Vertex Pharmaceuticals Inc — 2.74%
  10. Pfizer Inc — 2.61%

XLV top 10

  1. Eli Lilly & Co — 16.51%
  2. Johnson & Johnson — 10.64%
  3. AbbVie Inc — 7.74%
  4. UnitedHealth Group Inc — 6.57%
  5. Merck & Co Inc — 5.52%
  6. Amgen Inc — 3.40%
  7. Thermo Fisher Scientific Inc — 3.24%
  8. Abbott Laboratories — 2.75%
  9. Gilead Sciences Inc — 2.73%
  10. Intuitive Surgical Inc — 2.45%

FAQ

What is the difference between SHISX and XLV?
SHISX (Blackrock Health Sciences Opportunities Portfolio) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds. But SHISX is far broader, holding 155 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
Which is cheaper, SHISX or XLV?
XLV has the lower expense ratio (0.08%).
Should I own both SHISX and XLV?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.